COMMUNIQUÉS West-GlobeNewswire

Caring Brands Inc. and SanPellegrino Cosmetics Private Limited Announce Expanded Multi-Territory Licensing Agreement for Photocil and Hair Enzyme Booster
01/06/2026
Five-Year Agreement Extends Commercial Reach Across India, LATAM, Russia, Australia and New Zealand Fort Pierce, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR), a consumer brands company [...]
Ardena appoints Ariane de Ganck as Chief Scientific Officer
01/06/2026
Ghent, Belgium, June 1, 2026 - Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and complex therapies, today announced the appointment of Ariane de Ganck, PhD, as Chief [...]
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
01/06/2026
MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications [...]
Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657
01/06/2026
CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the extension of its C-Scrub [...]
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
01/06/2026
- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses an IV-delivered, [...]
Introducing Evosep Proteomics to Standardize and Scale Proteomics for Research and Drug Development
01/06/2026
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS–based proteomics for research and pharmaceutical drug development. [...]
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
01/06/2026
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
01/06/2026
TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based [...]
Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence
01/06/2026
The company introduces an expanded on-premise and hybrid C5ISR suite that enables local AI processing, command automation, and response coordination for defense, security, and critical infrastructure NETANYA, Israel, [...]
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
01/06/2026
Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura [...]
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
01/06/2026
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, [...]
Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis
01/06/2026
Renexxion plans to file new drug application (NDA) with the Food and Drug Administration (FDA) using future Phase 3 results ROSCREA, Ireland and FREIBURG, Germany, June 01, 2026 (GLOBE NEWSWIRE) -- Renexxion Ireland [...]
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
01/06/2026
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3 Confirmatory [...]
Wave Life Sciences to Present at Upcoming Investor Conferences
01/06/2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
01/06/2026
Preclinical data demonstrate robust T cell activation, durable immune memory, and lymph node-targeted mechanism supporting next-generation immunotherapies BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, [...]
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
01/06/2026
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
01/06/2026
FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illustrates the unique [...]
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
01/06/2026
55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability in heavily [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/06/2026
CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]

Pages